Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapeutics crawled date : 2022 - 05 - 09 save search
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
Published: 2022-05-09 (Crawled : 21:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.69%
H: 0.28%
C: -1.1%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.15%
H: 0.0%
C: 0.0%
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: -2.88%
H: 2.34%
C: -8.64%
therapeutics
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates
Published: 2022-05-09 (Crawled : 21:00) - biospace.com/
HRTX M | $2.63 -2.95% -3.04% 2.3M
|
Health Technology
|
| O: -1.7%
H: 1.36%
C: -10.64%
therapeutics
Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-05-09 (Crawled : 21:00) - atossatherapeutics.com
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: -2.41%
H: 3.93%
C: -1.24%
therapeutics results
Amicus Therapeutics Announces First Quarter 2022 Financial Results
Published: 2022-05-09 (Crawled : 14:20) - biospace.com/
FOLD F | $10.62 2.81% 2.73% 2.5M
|
Health Technology
|
| O: -9.35%
H: 14.81%
C: 3.66%
therapeutics results
BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights
Published: 2022-05-09 (Crawled : 14:20) - biospace.com/
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: -1.75%
H: 3.48%
C: -7.94%
therapeutics results
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma
Published: 2022-05-09 (Crawled : 14:00) - biospace.com/
ACHL | $0.7827 -2.16% -2.21% 200K
|
Manufacturing
|
| O: 0.46%
H: 1.84%
C: -9.68%
trial therapeutics enroll
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
Published: 2022-05-09 (Crawled : 13:20) - biospace.com/
FNCH | $2.205 -6.57% -7.03% 30K
|
Professional, Scientific, and T...
|
| O: -3.35%
H: 0.87%
C: -6.93%
conference therapeutics
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting
Published: 2022-05-09 (Crawled : 13:20) - globenewswire.com
CRXT | $0.0475
|
|
| O: -2.47%
H: 0.0%
C: -9.12%
jatenzo therapeutics
CORRECTING AND REPLACING -- Amicus Therapeutics Announces First Quarter 2022 Financial Results
Published: 2022-05-09 (Crawled : 13:20) - globenewswire.com
FOLD F | $10.62 2.81% 2.73% 2.5M
|
Health Technology
|
| O: -9.35%
H: 14.81%
C: 3.66%
therapeutics results
LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia
Published: 2022-05-09 (Crawled : 13:00) - biospace.com/
LOGC | $2.07 -0.48%
|
Health Technology
|
| O: 65.68%
H: 5.81%
C: -20.56%
fda trial therapeutics clinical hold
Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome PatientsPhase 3 DiSCOVER clinical trial initiation expected by end of Q2 2022
Published: 2022-05-09 (Crawled : 13:00) - biospace.com/
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: -2.83%
H: 0.97%
C: -9.22%
fda expected trial therapeutics phase 3
Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal
Published: 2022-05-09 (Crawled : 13:00) - allogene.com
ALLO | $3.48 0.58% 0.57% 2M
|
Health Technology
|
| O: -1.97%
H: 0.0%
C: -18.28%
bay therapeutics
Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight
Published: 2022-05-09 (Crawled : 13:00) - globenewswire.com
OTLK P | $8.15 -1.69% -1.72% 270K
|
Health Technology
|
| O: -0.95%
H: 0.0%
C: 0.0%
ceo therapeutics
Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic
Published: 2022-05-09 (Crawled : 12:20) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
therapeutics
Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference
Published: 2022-05-09 (Crawled : 12:20) - biospace.com/
XCUR 4 | $0.5825 0.64% 0.64% 22K
|
Commercial Services
|
| O: -4.31%
H: 0.25%
C: -16.58%
conference therapeutics
Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022
Published: 2022-05-09 (Crawled : 12:20) - globenewswire.com
SPRO | $1.41 -4.08% -4.26% 380K
|
Health Technology
|
| O: 21.05%
H: 8.21%
C: -8.7%
report therapeutics results
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
Published: 2022-05-09 (Crawled : 12:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -3.94%
H: 1.1%
C: -28.08%
therapeutics results
Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics
Published: 2022-05-09 (Crawled : 12:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -1.4%
H: 0.61%
C: -4.73%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -17.99%
H: 1.48%
C: -7.64%
sunosi therapeutics solriamfetol
AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors
Published: 2022-05-09 (Crawled : 12:00) - biospace.com/
ANTX | $2.43 2.1% 2.06% 100K
|
|
| O: -0.21%
H: 0.16%
C: -19.49%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.15%
H: 0.0%
C: 0.0%
therapeutics
ADC Therapeutics Announces CEO Transition
Published: 2022-05-09 (Crawled : 12:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -3.94%
H: 1.1%
C: -28.08%
ceo therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.